Related Experiment Video
Updated: Feb 11, 2026

Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
Anticholinergic drugs and risk of dementia: case-control study
Kathryn Richardson1, Chris Fox2, Ian Maidment3
1School of Health Sciences, University of East Anglia, Norwich NR4 7TJ, UK.
Objectives:
To estimate the association between the duration and level of exposure to different classes of anticholinergic drugs and subsequent incident dementia.
Design:
Case-control study.
Setting:
General practices in the UK contributing to the Clinical Practice Research Datalink.
Participants:
40 770 patients aged 65-99 with a diagnosis of dementia between April 2006 and July 2015, and 283 933 controls without dementia.
Interventions:
Daily defined doses of anticholinergic drugs coded using the Anticholinergic Cognitive Burden (ACB) scale, in total and grouped by subclass, prescribed 4-20 years before a diagnosis of dementia.
Main Outcome Measures:
Odds ratios for incident dementia, adjusted for a range of demographic and health related covariates.
Results:
14 453 (35%) cases and 86 403 (30%) controls were prescribed at least one anticholinergic drug with an ACB score of 3 (definite anticholinergic activity) during the exposure period. The adjusted odds ratio for any anticholinergic drug with an ACB score of 3 was 1.11 (95% confidence interval 1.08 to 1.14). Dementia was associated with an increasing average ACB score. When considered by drug class, gastrointestinal drugs with an ACB score of 3 were not distinctively linked to dementia. The risk of dementia increased with greater exposure for antidepressant, urological, and antiparkinson drugs with an ACB score of 3. This result was also observed for exposure 15-20 years before a diagnosis.
Conclusions:
A robust association between some classes of anticholinergic drugs and future dementia incidence was observed. This could be caused by a class specific effect, or by drugs being used for very early symptoms of dementia. Future research should examine anticholinergic drug classes as opposed to anticholinergic effects intrinsically or summing scales for anticholinergic exposure.
Trial Registration:
Registered to the European Union electronic Register of Post-Authorisation Studies EUPAS8705.
More Related Videos
06:48Lexical Decision Task for Studying Written Word Recognition in Adults with and without Dementia or Mild Cognitive Impairment
Published on: June 25, 2019
08:42Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression
Published on: May 19, 2015
Related Concept Videos
Dementia
The progression of dementia is generally gradual....
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Relative Risk
Drug Control Governance: Regulatory Bodies and Their Impact
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Methods for Studying Drug Absorption: In vitro
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...